For U.S. Healthcare Professionals Only
+|Aa|-

What is RenValueâ„ ?

  • Qualified patients with either commercial prescription insurance or no insurance can utilize the RenValue copay card program to help cover the out-of-pocket costs for Renvela®.
  • Learn more at RenValue.com

Who is eligible?

Patients with either commercial prescription insurance or no prescription insurance are eligible.1

Who is not eligible?

Patients participating in Medicaid, Medicare Part D, Veteran Affairs, Indian Health Service, or other federal or state programs are not eligible for this benefit.

What are the benefits?

  • For patients with commercial insurance:
    • Patients pay $5 for each of 12 fills for claims up to $300.1
  • For patients with no insurance:
    • Patients save up to $300 off out-of-pocket costs for each of 12 fills.1

Indication

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.

Please see additional Important Safety Information.

Please see full Prescribing Information for Renvela® or full Prescribing Information for Renagel®

The RenValue coupon program could help lower out-of-pocket costs for people with commercial insurance coverage.

Learn more at RenValue.com.

Indication

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

  • Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela® or full Prescribing Information for Renagel®.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Reference:

  1. Data on file, Sanofi US.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients. Click here to read more.